| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ajay Madan, Stacy Markison, Stephen F Betz, Alan Krasner, Rosa Luo, Theresa Jochelson, Jason Lickliter, R Scott Struther. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022-01-09. PMID:35000098. |
evaluate the pharmacodynamics, pharmacokinetics, and safety of paltusotine, an orally bioavailable, nonpeptide, somatostatin receptor subtype 2 (sst2) agonist being developed for the treatment of acromegaly and neuroendocrine tumors. |
2022-01-09 |
2023-08-13 |
human |
| Xiao-Qing Shao, Zheng-Yuan Chen, Meng Wang, Ye-Ping Yang, Yi-Fei Yu, Wen-Juan Liu, Yi Wang, Fang-Fang Zeng, Wei Gong, Hong-Ying Ye, Yong-Fei Wang, Yao Zhao, Li Zhang, Zhao-Yun Zhang, Min He, Yi-Ming L. Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Cases. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 54. issue 1. 2022-01-05. PMID:34986497. |
effects of long-acting somatostatin analogues on lipid metabolism in patients with newly diagnosed acromegaly: a retrospective study of 120 cases. |
2022-01-05 |
2023-08-13 |
Not clear |
| Xiao-Qing Shao, Zheng-Yuan Chen, Meng Wang, Ye-Ping Yang, Yi-Fei Yu, Wen-Juan Liu, Yi Wang, Fang-Fang Zeng, Wei Gong, Hong-Ying Ye, Yong-Fei Wang, Yao Zhao, Li Zhang, Zhao-Yun Zhang, Min He, Yi-Ming L. Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Cases. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 54. issue 1. 2022-01-05. PMID:34986497. |
the short-term effects of long-acting somatostatin analogues (ssas) on lipid profiles in patients with acromegaly are not well studied. |
2022-01-05 |
2023-08-13 |
Not clear |
| Anna Babinska, Hanna Olszewska, Krzysztof Sworcza. Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating. Neuro endocrinology letters. vol 42. issue 7. 2021-12-30. PMID:34969186. |
safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating. |
2021-12-30 |
2023-08-13 |
Not clear |
| Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut, Yulia G Pokramovich, Mark E Molitch, Nina Leonova, Gerald Raverot, Elena Grineva, Yury E Poteshkin, Yossi Gilgun-Sherki, William H Ludlam, Gary Patou, Asi Haviv, Murray B Gordon, Nienke R Biermasz, Shlomo Melmed, Christian J Strasburge. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. The lancet. Diabetes & endocrinology. 2021-12-26. PMID:34953531. |
maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. |
2021-12-26 |
2023-08-13 |
Not clear |
| Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut, Yulia G Pokramovich, Mark E Molitch, Nina Leonova, Gerald Raverot, Elena Grineva, Yury E Poteshkin, Yossi Gilgun-Sherki, William H Ludlam, Gary Patou, Asi Haviv, Murray B Gordon, Nienke R Biermasz, Shlomo Melmed, Christian J Strasburge. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. The lancet. Diabetes & endocrinology. 2021-12-26. PMID:34953531. |
despite biochemically responding to injectable somatostatin receptor ligands (isrls), many patients with acromegaly experience treatment burdens. |
2021-12-26 |
2023-08-13 |
Not clear |
| Taeheon Kim, Seungmok Choi, Duck-Soo Lim, Hwi-Yeol Yu. Bioanalysis of lanreotide in dog plasma using liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of beagle dogs after single subcutaneous injection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 1188. 2021-12-10. PMID:34891048. |
lanreotide is similar to a naturally occurring hormone, somatostatin; thus, it may be used to treat acromegaly or metastatic gastroenteropancreatic neuroendocrine tumours. |
2021-12-10 |
2023-08-13 |
dog |
| Hiroyuki Iida, Tatsuya Komagata, Hirotaka Tanaka, Ryusuke Nagasawa, Takuya Nishio, Tomoyuki Shono, Junsaku Kitagawa, Ken-Ichi Ogawara, Koji Shinozaki, Akiteru Seki, Mark Bruce, Tomoya Ohn. Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone-Inhibitory Effect of Octreotide after Growth Hormone-Releasing Hormone Stimulation. The Journal of pharmacology and experimental therapeutics. vol 379. issue 3. 2021-12-03. PMID:34599040. |
we evaluated the e-r relationship of the growth hormone (gh)-inhibitory effect of the somatostatin analog octreotide under growth hormone-releasing hormone + arginine stimulation in healthy participants and compared the results with historical data for patients with acromegaly. |
2021-12-03 |
2023-08-13 |
human |
| Marco Losa, Eugenia Resmini, Lina R Barzaghi, Luigi Albano, Michele Bailo, Susan M Webb, Pietro Mortin. Resistance to first-generation somatostatin receptor ligands does not impair the results of gamma knife radiosurgery in acromegaly. Clinical endocrinology. vol 95. issue 6. 2021-11-19. PMID:34219264. |
resistance to first-generation somatostatin receptor ligands does not impair the results of gamma knife radiosurgery in acromegaly. |
2021-11-19 |
2023-08-13 |
Not clear |
| Hakan Korkmaz, Kuyaş Hekimler Öztürk, Bora Toru. Circulating miR-29c-3p is downregulated in patients with acromegaly Turkish journal of medical sciences. vol 51. issue 4. 2021-11-18. PMID:34013701. |
another aim is to investigate whether there is a difference in the levels of these mirnas in patients with inadequate control and controlled acromegaly with somatostatin analog (ssa) therapy. |
2021-11-18 |
2023-08-13 |
Not clear |
| Federica Nista, Giuliana Corica, Lara Castelletti, Keyvan Khorrami, Claudia Campana, Francesco Cocchiara, Gabriele Zoppoli, Alessandro Prior, Diego Criminelli Rossi, Gianluigi Zona, Diego Ferone, Federico Gatt. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. Frontiers in endocrinology. vol 12. 2021-11-18. PMID:34025586. |
clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective. |
2021-11-18 |
2023-08-13 |
Not clear |
| Federica Nista, Giuliana Corica, Lara Castelletti, Keyvan Khorrami, Claudia Campana, Francesco Cocchiara, Gabriele Zoppoli, Alessandro Prior, Diego Criminelli Rossi, Gianluigi Zona, Diego Ferone, Federico Gatt. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. Frontiers in endocrinology. vol 12. 2021-11-18. PMID:34025586. |
first-generation somatostatin receptor ligands (fg-srls) represent the first-line medical treatment for acromegaly, recommended in patients with persistent disease after neurosurgery, or when surgical approach is not feasible. |
2021-11-18 |
2023-08-13 |
Not clear |
| E Sala, G Carosi, G Del Sindaco, R Mungari, A Cremaschi, A L Serban, C L Ronchi, E Ferrante, M Arosio, G Mantovan. Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience. Journal of endocrinological investigation. vol 44. issue 12. 2021-11-17. PMID:34018167. |
long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience. |
2021-11-17 |
2023-08-13 |
Not clear |
| E Sala, G Carosi, G Del Sindaco, R Mungari, A Cremaschi, A L Serban, C L Ronchi, E Ferrante, M Arosio, G Mantovan. Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience. Journal of endocrinological investigation. vol 44. issue 12. 2021-11-17. PMID:34018167. |
a long-lasting remission of acromegaly after somatostatin analogues (sas) withdrawal has been described in some series. |
2021-11-17 |
2023-08-13 |
Not clear |
| Artak Labadzhyan, L B Nachtigall, M Fleseriu, M B Gordon, M Molitch, L Kennedy, S L Samson, Y Greenman, N Biermasz, M Bolanowski, A Haviv, W Ludlam, G Patou, C J Strasburge. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary. vol 24. issue 6. 2021-11-11. PMID:34173129. |
results are presented from 2 to 3 trials investigating oral octreotide capsules (ooc) as an alternative to injectable somatostatin receptor ligands (isrls) in the treatment of acromegaly. |
2021-11-11 |
2023-08-13 |
Not clear |
| Serdar Sahin, Tevhide Betul Icli, Emre Durcan, Cem Sulu, Hande Mefkure Ozkaya, Ali Ibrahim Hatemi, Pinar Kadiogl. The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. Pituitary. vol 24. issue 2. 2021-11-04. PMID:33074400. |
the effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. |
2021-11-04 |
2023-08-13 |
Not clear |
| Serdar Sahin, Tevhide Betul Icli, Emre Durcan, Cem Sulu, Hande Mefkure Ozkaya, Ali Ibrahim Hatemi, Pinar Kadiogl. The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. Pituitary. vol 24. issue 2. 2021-11-04. PMID:33074400. |
to evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly. |
2021-11-04 |
2023-08-13 |
Not clear |
| b' Betina Biagetti, Anna Aulinas, Anna Casteras, Santiago P\\xc3\\xa9rez-Hoyos, Rafael Sim\\xc3\\xb. HOMA-IR in acromegaly: a systematic review and meta-analysis. Pituitary. vol 24. issue 2. 2021-11-04. PMID:33085039.' |
this review is aimed at examining whether the homeostatic model assessment of insulin resistance (homa-ir) is higher in caucasian, adult, treatment-naïve patients with acromegaly (acro) than in the reference population independently of diabetes presence and to evaluate the impact of treatment [surgery and somatostatin analogues (ssas)] on its assessment. |
2021-11-04 |
2023-08-13 |
Not clear |
| N Prencipe, C Bona, D Cuboni, M Parasiliti-Caprino, A M Berton, L M Fenoglio, V Gasco, E Ghigo, S Grottol. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment. Pituitary. vol 24. issue 2. 2021-11-04. PMID:33164134. |
biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment. |
2021-11-04 |
2023-08-13 |
Not clear |
| N Prencipe, C Bona, D Cuboni, M Parasiliti-Caprino, A M Berton, L M Fenoglio, V Gasco, E Ghigo, S Grottol. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment. Pituitary. vol 24. issue 2. 2021-11-04. PMID:33164134. |
somatostatin receptor ligands (srl) are the first-line medical treatment for acromegaly. |
2021-11-04 |
2023-08-13 |
Not clear |